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CASE REPORT
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Abstract
Wolf-Parkinson-White (WPW) syndrome is a congenital heart condition in which the atrioventricular (AV) node is
bypassed by an accessory pathway that connects the atria and ventricle directly. WPW syndrome in patients with a
history of peripartum cardiomyopathy (pregnancy-related cardiomyopathy) is associated with a high risk of morbidity
and mortality secondary to failure of the pump and the conduction system of the heart. Management of these cases deals
with arrhythmia and systolic heart failure, which becomes more challenging in pregnant patients as it requires treatment
methods that minimize risks to the fetus. We report a case of a young female patient with WPW syndrome and postpartum cardiomyopathy presenting with symptomatic arrhythmias (tachycardia).
Keywords: Wolf-Parkinson-White (WPW), Postpartum cardiomyopathy, Arrhythmias, Tachycardia

1. Introduction

W

olf-Parkinson-White (WPW) syndrome is a
congenital heart disease in which an
accessory pathway directly connects the atria and
ventricle, bypassing the atrioventricular (AV) node.
The characteristic WPW pattern EKG includes a
short PR interval (0.12 s) and a delta wave with a
wide (0.12 s) QRS complex. The delta wave results
from rapid ventricular activation via the accessory
pathway (preexcitation). In the general population,
the prevalence of WPW pattern EKG is around 0.13
to 0.25 percent. In comparison prevalence of WPW
syndrome is as low as 2 percent of patients with
WPW patterns on surface EKG.
Diagnostic criteria involve pre-existing WPW patterns on EKG and arrhythmia involving the accessory
pathway. Asymptomatic adults with WPW patterns
are generally not treated. In contrast, those with
symptomatic arrhythmias should be treated. We
report a case of a young female patient with WPW
syndrome and postpartum cardiomyopathy presenting with symptomatic arrhythmias (tachycardia).

2. Case presentation
29-year-old African American female with a past
medical history of opiate abuse and currently two
months into her post-partum period presented to ED
complaining of constant, sharp left-sided chest pain
for the past four days which was mildly relieved with
ibuprofen. She described it to be exacerbated by deep
breaths and associated with cough and blood-tinged
sputum. She endorsed palpitations lasting all day long
and two episodes of non-bloody, non-bilious emesis.
Reported bilateral lower extremity edema with associated orthopnea and PND, for which she uses 2e3
pillows at night. Of note, she is bed-bound most of the
time, secondary to her lower extremity swelling.
This was her fourth pregnancy and she reported
having similar symptoms in her prior post-partum
periods as well but was never formally evaluated.
In ED, the patient was found to have a BP of 76/50.
EKG (EKG a) showed AVNRT with a nonspeciﬁc
intraventricular block and a heart rate of 190 beats
per minute, likely secondary to WPW syndrome.
Also, a QTc of 533 ms on noted. Serum magnesium
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was 1.6 mg/dl, which was repleted. She was treated
with two doses of 100 mg intravenous procainamide,
which reverted the cardiac rhythm to sinus rhythm
and raised the patients blood pressure to 110/
70 mmHg. A white blood cell of 12.4/mm3 (Normal
range 4e10) was noted. Brain natriuretic peptide
levels were 916 pg/ml (Normal <100). Chest X-ray
showed ﬁndings suggestive of a small left pleural
effusion; CT angiography was negative for Pulmonary embolism but did show ﬁndings concerning
left lower lobe bronchopneumonia with trace
pericardial and bilateral pleural effusions. The patient was given ceftriaxone and doxycycline, was
continued on procainamide infusion and admitted
to the Intensive care unit for further management.
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Cardiology was consulted, a transthoracic echocardiogram showed a left ventricular ejection fraction of less than twenty percent with moderate left
ventricular hypertrophy and a moderate to severe
tricuspid regurgitation. The following day, an electrocardiogram showed conversion to sinus rhythm
with a heart rate of 100se120s (EKG b). Procainamide
was eventually discontinued, and she was started on
intravenous furosemide infusion. Serum magnesium
of greater than 2 mg/dl and potassium levels of
greater than four mmol/l were maintained. The
patient remained afebrile with improving leukocytosis; MRSA screen was negative, and blood cultures
did not show any growth. She was continued on
Ceftriaxone 2 g IV daily and doxycycline 100 mg PO
BID given her QTC prolongation.
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The patient was then transferred to a super-specialty center for further management, where she was
placed on a life vest. Dobutamine and milrinone
drip was started with visiting nurse as temporizing
measures, and the patient is now being evaluated for
left ventricular assist device implantation.

3. Discussion
Peripartum Cardiomyopathy (PPCM), also called
pregnancy-associated cardiomyopathy, is an uncommon cause of heart failure during late pregnancy
or early postpartum period. It is associated with
signiﬁcant morbidity and mortality related to heart
failure and arrhythmias, which usually result from
stretching of atrial and ventricular chambers.1,2 It is
estimated to account for less than 1% of pregnancyassociated cardiovascular complications, but the
incidence has been increasing. In a large inpatientbased study on 9841 patients hospitalized for PPCM,
18.7% of the patients had an arrhythmia, of which
4.2% had ventricular arrhythmia, and 2.2% suffered
cardiac arrest.2,3 WPW syndrome is a pre-excitation/
accessory pathway induced arrhythmia associated
with pregnancy and can be seen in combination with
PPCM, which involves simultaneous management of
systolic dysfunction and can get challenging at times.
Management of arrhythmias during pregnancy is
more or less similar to that of a non-pregnant state.
However, care should be taken to avoid any detrimental effects on fetal well-being due to therapy or
the underlying condition. Several AV nodal blocking agents are considered safe for supraventricular
tachycardia during pregnancy; however, in patients
with WPW syndrome, AV nodal blocking agents are
contraindicated or are cautiously used due to the
potential for life-threatening ventricular ﬁbrillation.4 Class IA antiarrhythmics like procainamide,
quinidine, and Class IC antiarrhythmics like propafenone, ﬂecainide are considered safe when there
is no associated ischemic or structural heart disease.
For these reasons, managing patients with WPW
syndrome and simultaneous PPCM is a challenge
and requires multidisciplinary team management as
PPCM therapy involves using beta-blockers to
manage the underlying heart failure.
In comparison, Class IC drugs are associated with a
better beneﬁt/risk ratio, whereas Class IA drugs have
been noticed to be less potent than Class IC drugs and
are associated with intolerable side effects.5,6 Procainamide produces a lengthening of the refractory
period of the accessory pathway in AVRT or of the
fast pathway in AVNRT to terminate the re-entry
tachycardia.12 Beta blocking agents are occasionally
used to suppress orthodromic AVRT in those with

WPW syndrome with a low risk of ventricular
tachyarrhythmias due to pre-excitation. Of note,
AVRT occurs in two types: orthodromic and
antidromic. Orthodromic AVRT re-entry impulse
circulates in an antegrade direction through the AV
node; in antidromic AVRT, the impulse travels in a
retrograde direction through the AV node.
Amiodarone is effective but has signiﬁcant side
effects; thus, it can be employed in patients where
other therapies failed or are not feasible. As per 2014
AHA guidelines, for patients with pre-excitation and
rapid ventricular rate, management involves intravenous procainamide in hemodynamically stable
patients and synchronized cardioversion in unstable
ones. In a small, non-randomized trial containing a
subset of patients with AVRT, ten patients treated
with a combination of propafenone and betablocker therapy had no recurrence at >9 months
after discharge.7 Cardioversion can be performed
during any week of pregnancy; although there is a
theoretical risk of triggering an arrhythmia in the
fetus, the risk is supposed to be small due to the
small amount of energy directly reaching the fetus
itself.8,9 However, there have been cases reported of
fetal arrhythmias requiring emergent C-section
after cardioversion, and hence monitoring fetal
heart rhythm is recommended.10
As per 2015 ACC/AHA/HRC guidelines, vagal maneuvers and IV adenosine are Class 1 A recommendations for orthodromic AVRT. In a hemodynamically
stable patient where vagal maneuvers or adenosine is
ineffective or not feasible, radiofrequency ablation can
be performed as a class 1 recommendation irrespective of the patient's EKG demonstrating preexcitation. If the patient is unstable, synchronized
cardioversion is recommended (Class 1).
If the patient has pre-excitation and is unwilling to
undergo ablation, medications including ﬂecainide
or propafenone (in the absence of structural heart
disease (SHD))can be used as Class IIa recommendations. Amiodarone, beta-blockers, diltiazem,
dofetilide, sotalol, or verapamil can be used as Class
IIb recommendation. There is a class 1 recommendation for beta-blockers, diltiazem, or verapamil if
there is no pre-excitation. If any of the aforementioned medications in the presence or absence of
pre-excitation are ineffective, it is a class 1 indication
for ablation.
After an acute event, radiofrequency ablation of the
accessory pathway is recommended to prevent
recurrent episodes of arrhythmia in patients with
WPW syndrome. This procedure is generally avoided
during pregnancy due to the risk of exposure of the
fetus to ionizing radiation. However, as the amount of
radiation is small and only involves the area of the

thorax of the mother for the procedure, patients with
drug-resistant and severe arrhythmias during pregnancy can be considered for this procedure provided
adequate precautionary measures to minimize fetal
radiation exposure are undertaken.11

4. Conclusion
Although peripartum cardiomyopathy is rare, it is
associated with signiﬁcant morbidity and mortality
from both systolic heart failure and arrhythmias’
especially in cases of underlying WPW syndrome.
Treatment involves using class Ia and III antiarrhythmic agents in the absence of structural or
ischemic heart disease. Beta-blockers can also be
used to manage heart failure in patients with orthodromic AVRT and low risk of ventricular arrhythmia.
Unstable patients need synchronized cardioversion which carries a risk of fetal arrhythmia, and
fetal cardiac monitoring is recommended during the
procedure.
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